SCHEMBL27218664

SCHEMBL27218664

Nc1nc(N)nc(SCc2nc(-c3cccc(C(F)(F)F)c3)no2)n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 1/20 0.57
▸ NPC1 O15118 3/20 0.49
▸ RAB9A P51151 3/20 0.49
▸ SMN1; SMN2 Q16637 3/20 0.49
▸ LMNA P02545 1/20 0.49
▸ HTT P42858 1/20 0.49
▸ S1PR1 P21453 2/20 0.48
▸ TDP1 Q9NUW8 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ NR1H4 Q96RI1 1/20 0.46
▸ FFAR1 O14842 2/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.45
▸ CASP3 P42574 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ MAPT P10636 1/20 0.43
▸ ALOX15 P16050 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11919088 0.79 NR1H4 (0.57) TP53NPC1RAB9ASMN1; SMN2S1PR1
SCHEMBL30566776 0.76 S1PR1 (0.57) TP53NPC1RAB9ASMN1; SMN2S1PR1
SCHEMBL2245424 0.76 S1PR1 (0.57) TP53NPC1RAB9ASMN1; SMN2S1PR1
SCHEMBL24800013 0.75 NPC1 (0.63) NPC1RAB9ASMN1; SMN2S1PR1NR1H4
SCHEMBL27218734 0.74 S1PR1 (0.46) TP53NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL27218787 0.74 RAB9A (0.54) NPC1RAB9ASMN1; SMN2LMNAHTT
SCHEMBL1065562 0.74 RAB9A (0.56) NPC1RAB9ALMNAKDM4EGAA
SCHEMBL29803503 0.74 RAB9A (0.56) NPC1RAB9ALMNAKDM4EGAA
SCHEMBL27218882 0.72 ALDH1A1 (0.43) SMN1; SMN2LMNAL3MBTL1NPSR1ALDH1A1
SCHEMBL27218893 0.71 S1PR1 (0.47) TP53NPC1RAB9ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4232448-B1 AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR Halo Therapeutics Ltd (GB) 2025-05-07 — — EP disclosed
EP-3956323-B1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 Halo Therapeutics Ltd (GB) 2025-03-05 — — EP disclosed
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor Halo Therapeutics Ltd (GB) 2024-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor FFAR1, FFAR2, FFAR3 TP53 4635/4885NPC1 781/4885RAB9A 2474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback